Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DSGN Stock Forecast 2026-2027
$12.61
Current Price
$844.42M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DSGN Price Targets
+74.5%
To High Target of $22.00
+66.5%
To Median Target of $21.00
+58.6%
To Low Target of $20.00
DSGN Price Momentum
-17.0%
1 Week Change
+5.7%
1 Month Change
+213.7%
1 Year Change
+34.4%
Year-to-Date Change
-26.9%
From 52W High of $17.25
+235.4%
From 52W Low of $3.76
📊 TOP ANALYST CALLS
Did DSGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Design Therapeutics is one of their latest high-conviction picks.
Latest DSGN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, DSGN has a bullish consensus with a median price target of $21.00 (ranging from $20.00 to $22.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $12.61, the median forecast implies a 66.5% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DSGN Analyst Ratings
7
Buy
0
Hold
0
Sell
DSGN Price Target Range
Low
$20.00
Average
$21.00
High
$22.00
Current: $12.61
Latest DSGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DSGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 4, 2026 | Oppenheimer | Kostas Biliouris | Outperform | Maintains | $21.00 |
| Mar 16, 2026 | Jefferies | Buy | Initiates | $N/A | |
| Mar 10, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Jan 7, 2026 | Oppenheimer | Outperform | Initiates | $N/A | |
| Dec 3, 2025 | Leerink Partners | Outperform | Upgrade | $N/A | |
| Nov 20, 2025 | RBC Capital | Outperform | Upgrade | $N/A | |
| Nov 6, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Aug 6, 2024 | RBC Capital | Sector Perform | Reiterates | $N/A | |
| May 7, 2024 | Piper Sandler | Overweight | Upgrade | $N/A | |
| Mar 20, 2024 | RBC Capital | Sector Perform | Reiterates | $N/A | |
| Mar 20, 2024 | Wedbush | Neutral | Reiterates | $N/A | |
| Nov 14, 2023 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Aug 15, 2023 | Wedbush | Neutral | Downgrade | $N/A | |
| Aug 15, 2023 | SVB Leerink | Market Perform | Downgrade | $N/A | |
| Aug 15, 2023 | RBC Capital | Sector Perform | Downgrade | $N/A | |
| May 10, 2023 | RBC Capital | Outperform | Maintains | $N/A | |
| May 10, 2023 | Wedbush | Outperform | Maintains | $N/A | |
| May 4, 2023 | Goldman Sachs | Neutral | Upgrade | $N/A | |
| Mar 15, 2023 | RBC Capital | Outperform | Reiterates | $N/A | |
| Dec 9, 2022 | SVB Leerink | Outperform | Maintains | $N/A |
Design Therapeutics, Inc. (DSGN) Competitors
The following stocks are similar to Design Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DSGN
Design Therapeutics
mkt cap
948.72M
Design Therapeutics, Inc. (DSGN) Financial Data
Design Therapeutics, Inc. has a market capitalization of $844.42M with a P/E ratio of -11.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -31.3%.
Valuation Metrics
Market Cap
$844.42M
Enterprise Value
$645.25M
P/E Ratio
-11.1x
PEG Ratio
1.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+28.3%
Current Ratio
22.3x
Debt/Equity
1.3x
ROE
-31.3%
ROA
-20.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Design Therapeutics, Inc. (DSGN) Business Model
About Design Therapeutics, Inc.
What They Do
Develops treatments for serious degenerative disorders.
Business Model
The company leverages a proprietary technology platform to create GeneTAC™ molecules that target and modulate dysfunctional genes. By addressing the genetic causes of rare inherited diseases, Design Therapeutics generates revenue through the development and potential commercialization of innovative therapies aimed at improving patient outcomes.
Additional Information
Design Therapeutics is positioned in the health sector, focusing on rare genetic and neurological diseases, and aims to enhance personalized medicine through its advanced biotechnology solutions. Their commitment to bridging genetic research and clinical application emphasizes the company's potential impact on patients with limited treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
54
CEO
Mr. Pratik Shah Ph.D.
Country
United States
IPO Year
2021
Website
www.designtx.comDesign Therapeutics, Inc. (DSGN) Latest News & Analysis
Latest News
Quick Summary
Design Therapeutics, Inc. (Nasdaq: DSGN) has started patient dosing in a Phase 1 clinical trial for DT-818, targeting myotonic dystrophy type-1 (DM1).
Why It Matters
The initiation of a Phase 1 trial for DT-818 could lead to significant advancements in treating DM1, potentially increasing Design Therapeutics' market value and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Design Therapeutics utilizes its GeneTAC platform to develop DT-216P2 for Friedreich's Ataxia (FA). The ongoing RESTORE-FA trial supports the drug's credibility.
Why It Matters
Design Therapeutics' GeneTAC platform and positive trial data for DT-216P2 enhance its credibility, potentially boosting its market value and attractiveness to investors focused on biotech innovations.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Design Therapeutics, Inc. (Nasdaq: DSGN) will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m.
Why It Matters
Design Therapeutics' participation in a prominent healthcare conference could signal potential updates on their drug development progress, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Design Therapeutics shares surged initially on positive results for Friedreich's ataxia but subsequently declined, erasing those gains.
Why It Matters
The volatility in Design Therapeutics' stock reflects market uncertainty and highlights risks in biotech investments, where initial positive news can quickly reverse.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Design Therapeutics Inc. (NASDAQ:DSGN) experienced a significant stock surge during the premarket session on Monday.
Why It Matters
A premarket surge in Design Therapeutics Inc. stock may indicate positive investor sentiment or news, potentially influencing trading decisions and market momentum.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Design Therapeutics, Inc. (DSGN) has presented data from the RESTORE-FA trial for its treatment DT-216P2 targeting Friedreich Ataxia.
Why It Matters
The discussion of RESTORE-FA trial data for DT-216P2 indicates potential breakthroughs in treatment for Friedreich Ataxia, which could influence stock performance and investor sentiment in biotechnology.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About DSGN Stock
What is Design Therapeutics, Inc.'s (DSGN) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Design Therapeutics, Inc. (DSGN) has a median price target of $21.00. The highest price target is $22.00 and the lowest is $20.00.
Is DSGN stock a good investment in 2027?
According to current analyst ratings, DSGN has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DSGN stock?
Wall Street analysts predict DSGN stock could reach $21.00 in the next 12 months. This represents a 66.5% increase from the current price of $12.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Design Therapeutics, Inc.'s business model?
The company leverages a proprietary technology platform to create GeneTAC™ molecules that target and modulate dysfunctional genes. By addressing the genetic causes of rare inherited diseases, Design Therapeutics generates revenue through the development and potential commercialization of innovative therapies aimed at improving patient outcomes.
What is the highest forecasted price for DSGN Design Therapeutics, Inc.?
The highest price target for DSGN is $22.00 from at , which represents a 74.5% increase from the current price of $12.61.
What is the lowest forecasted price for DSGN Design Therapeutics, Inc.?
The lowest price target for DSGN is $20.00 from at , which represents a 58.6% increase from the current price of $12.61.
What is the overall DSGN consensus from analysts for Design Therapeutics, Inc.?
The overall analyst consensus for DSGN is bullish. Out of 2 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are DSGN stock price projections?
Stock price projections, including those for Design Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:27 AM UTC